Compare Brookfield Infrastructure Partners LP (BIP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Neurocrine Biosciences Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39 (market cap $18.10B), while Neurocrine Biosciences Inc trades at $161.12 (market cap $16.46B). The key difference: Brookfield Infrastructure Partners LP and Neurocrine Biosciences Inc are close in size by market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BIP | NBIX | |
|---|---|---|
Market Cap | $18.10B | $16.46B |
Sector | Industrials | Health |
52-Week High | $42.62 | $185.50 |
52-Week Low | $29.81 | $123.10 |
Enterprise Value | $77.05B | $16.48B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.04, up 0.26% on the day, with a bullish technical signal and strong analyst support. The stock shows a high P/E ratio of 61.26 but attractive EV/EBITDA of 6.91, while recent earnings misses in Q4 2025 and Q1-Q2 2026 contrast with positive cash flow trends and a 2.6% net income margin. Recent news highlights dividend strength and corporate simplification efforts.
Outlook remains positive with a consensus price target of $44.67, offering ~14% upside, supported by bullish sentiment and infrastructure demand. Risks include earnings volatility, high debt-to-asset ratio of 69.68%, and macroeconomic pressures on profitability. The dividend yield and institutional interest provide stability, but execution on guidance is critical.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
